Asset Management One Co. Ltd. Reduces Position in Teva Pharmaceutical Industries Limited (TEVA)

Asset Management One Co. Ltd. lowered its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,373,240 shares of the company’s stock after selling 28,350 shares during the period. Asset Management One Co. Ltd. owned about 0.14% of Teva Pharmaceutical Industries worth $24,141,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in TEVA. Capital Research Global Investors raised its stake in shares of Teva Pharmaceutical Industries by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Teva Pharmaceutical Industries by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after acquiring an additional 6,685,844 shares during the last quarter. FMR LLC raised its stake in shares of Teva Pharmaceutical Industries by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after acquiring an additional 6,115,853 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 350.3% during the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after acquiring an additional 3,429,448 shares during the last quarter. Finally, Capital World Investors raised its stake in shares of Teva Pharmaceutical Industries by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after acquiring an additional 3,268,200 shares during the last quarter. 52.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (TEVA) traded down $0.05 during trading hours on Tuesday, reaching $16.39. 17,329,042 shares of the company’s stock were exchanged, compared to its average volume of 15,790,248. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The firm has a market capitalization of $16,316.96, a PE ratio of 3.71 and a beta of 0.55. Teva Pharmaceutical Industries Limited has a 1-year low of $10.85 and a 1-year high of $38.31.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is -12.10%.

Several equities analysts have recently issued reports on TEVA shares. TheStreet downgraded shares of Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. ValuEngine cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Evercore ISI set a $38.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, October 26th. Finally, Credit Suisse Group cut shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Seven investment analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and an average price target of $19.18.

COPYRIGHT VIOLATION WARNING: “Asset Management One Co. Ltd. Reduces Position in Teva Pharmaceutical Industries Limited (TEVA)” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2017/12/12/asset-management-one-co-ltd-reduces-position-in-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply